News from theravida, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 02, 2013, 08:00 ET

TheraVida and SK Chemicals Announce License Agreement for the Development and Commercialization of THVD-201 and THVD-202 for Overactive Bladder in South Korea

 TheraVida, Inc. and SK Chemicals Co., Ltd. (KRX: 006120) announced today the execution of a license agreement for two of TheraVida's...

Mar 18, 2013, 13:15 ET

TheraVida Presents Positive Phase 2 Data for Tolenix™ (THVD-201) in Patients with Overactive Bladder at the 28th Annual Congress of the European Urological Association

TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, presented positive results from a Phase 2...

Jan 03, 2013, 08:30 ET

TheraVida Announces Positive Top-Line Phase 2 Results for Tolenix™ (THVD-201) in Patients with Overactive Bladder and Urge Urinary Incontinence

TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, announced positive results from a Phase 2...

Oct 17, 2012, 07:07 ET

TheraVida Presents Positive Proof-of-Concept Results at the 2012 International Continence Society (ICS) Annual Meeting

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, announced positive results from two small...

May 13, 2011, 15:24 ET

TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence

MOUNTAIN VIEW, Calif., and SYDNEY, May 16, 2011 /PRNewswire-iReach/ -- TheraVida, Inc., a clinical stage biopharmaceutical company developing novel...

Mar 22, 2011, 19:35 ET

TheraVida Announces Positive Results From a Phase 1 Trial of THVD-201 for Overactive Bladder at the 2011 Annual Congress of the European Association of Urology

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a...